$BMRN
BIOMARIN PHARMACEUTICAL INC

2022 Q3 Form 10-Q Financial Statement

#000104847722000027 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $505.3M $533.8M $519.4M
YoY Change 23.63% 6.4% 6.86%
Cost Of Revenue $116.3M $123.1M $117.0M
YoY Change 12.32% -3.1% -2.66%
Gross Profit $389.1M $410.7M $402.4M
YoY Change 27.47% 9.62% 9.98%
Gross Profit Margin 76.99% 76.93% 77.48%
Selling, General & Admin $216.8M $196.8M $194.6M
YoY Change 18.26% 6.88% 11.65%
% of Gross Profit 55.73% 47.93% 48.37%
Research & Development $157.8M $158.2M $160.8M
YoY Change -0.03% -1.81% 8.14%
% of Gross Profit 40.57% 38.52% 39.97%
Depreciation & Amortization $24.80M $9.500M $27.34M
YoY Change 117.56% -19.49% -2.29%
% of Gross Profit 6.37% 2.31% 6.8%
Operating Expenses $391.5M $355.0M $355.5M
YoY Change 14.73% 2.83% 10.03%
Operating Profit -$2.417M $39.15M $137.3M
YoY Change -95.46% 235.44% 447.42%
Interest Expense $320.0K $3.859M $3.806M
YoY Change -91.73% 1.1% 0.05%
% of Operating Profit 9.86% 2.77%
Other Income/Expense, Net $193.0K -$2.947M -$1.154M
YoY Change -97.84% -246.98% -228.22%
Pretax Income -$1.904M $34.85M $134.2M
YoY Change -95.88% 146.19% 477.7%
Income Tax $4.748M $7.187M $13.39M
% Of Pretax Income 20.62% 9.98%
Net Earnings -$6.652M $27.66M $120.8M
YoY Change -81.77% 113.77% 595.4%
Net Earnings / Revenue -1.32% 5.18% 23.26%
Basic Earnings Per Share -$0.04 $0.15 $0.66
Diluted Earnings Per Share -$35.84K $0.15 $0.63
COMMON SHARES
Basic Shares Outstanding 185.5M shares 185.3M shares 184.0M shares
Diluted Shares Outstanding 185.6M shares 187.4M shares 194.9M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.274B $1.110B $1.056B
YoY Change 18.0% -1.22% -2.87%
Cash & Equivalents $761.5M $619.8M $605.4M
Short-Term Investments $512.3M $489.9M $450.8M
Other Short-Term Assets $149.9M $139.0M $121.3M
YoY Change 39.07% 40.37% 32.91%
Inventory $839.5M $802.3M $786.4M
Prepaid Expenses
Receivables $419.6M $466.5M $430.1M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.683B $2.518B $2.394B
YoY Change 16.06% 6.78% 4.6%
LONG-TERM ASSETS
Property, Plant & Equipment $1.052B $1.049B $1.040B
YoY Change 2.64% 2.23% 1.67%
Goodwill $196.2M $196.2M $196.2M
YoY Change 0.0% 0.0% 0.0%
Intangibles $354.0M $369.4M $374.3M
YoY Change -8.87% -6.32% -7.8%
Long-Term Investments $372.3M $412.5M $462.8M
YoY Change -20.21% 17.78% 44.14%
Other Assets $1.607B $151.8M $149.2M
YoY Change 1010.53% 7.15% 5.66%
Total Long-Term Assets $3.581B $3.628B $3.669B
YoY Change -2.31% 2.47% 4.33%
TOTAL ASSETS
Total Short-Term Assets $2.683B $2.518B $2.394B
Total Long-Term Assets $3.581B $3.628B $3.669B
Total Assets $6.264B $6.146B $6.063B
YoY Change 4.79% 4.19% 4.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $207.2M $199.3M $187.8M
YoY Change 1.89% 13.16% 13.82%
Accrued Expenses $264.1M $218.2M $214.4M
YoY Change 9.32% 5.41% 2.5%
Deferred Revenue $415.0K $305.0K $306.0K
YoY Change -95.7% -97.23% -97.27%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $521.0M $464.7M $490.4M
YoY Change 1.19% 4.82% 14.04%
LONG-TERM LIABILITIES
Long-Term Debt $1.082B $1.081B $1.080B
YoY Change 0.37% 0.37% 0.37%
Other Long-Term Liabilities $92.47M $95.26M $100.9M
YoY Change -10.33% -9.89% -6.33%
Total Long-Term Liabilities $1.175B $95.26M $100.9M
YoY Change 1038.85% -9.89% -6.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $521.0M $464.7M $490.4M
Total Long-Term Liabilities $1.175B $95.26M $100.9M
Total Liabilities $1.696B $1.641B $1.671B
YoY Change -0.92% -0.96% 1.73%
SHAREHOLDERS EQUITY
Retained Earnings -$788.9M -$777.2M -$804.9M
YoY Change -9.09% -6.5% -4.66%
Common Stock $5.336B $5.273B $5.206B
YoY Change 3.94% 3.71% 3.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.569B $4.505B $4.391B
YoY Change
Total Liabilities & Shareholders Equity $6.264B $6.146B $6.063B
YoY Change 4.79% 4.19% 4.44%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.652M $27.66M $120.8M
YoY Change -81.77% 113.77% 595.4%
Depreciation, Depletion And Amortization $24.80M $9.500M $27.34M
YoY Change 117.56% -19.49% -2.29%
Cash From Operating Activities $158.3M $56.23M -$45.43M
YoY Change 63.12% -32.09% -140.02%
INVESTING ACTIVITIES
Capital Expenditures -$36.47M -$28.04M $28.82M
YoY Change 79.13% 6.98% 12.98%
Acquisitions
YoY Change
Other Investing Activities $13.07M -$1.664M $118.5M
YoY Change -113.14% -98.23%
Cash From Investing Activities -$23.40M -$29.70M $87.78M
YoY Change -80.47% -75.3% -224.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.541M -11.78M -$25.28M
YoY Change -831.43% -207.22% 3.76%
NET CHANGE
Cash From Operating Activities 158.3M 56.23M -$45.43M
Cash From Investing Activities -23.40M -29.70M $87.78M
Cash From Financing Activities 7.541M -11.78M -$25.28M
Net Change In Cash 142.5M 14.75M $18.16M
YoY Change -698.12% -155.73% 0.05%
FREE CASH FLOW
Cash From Operating Activities $158.3M $56.23M -$45.43M
Capital Expenditures -$36.47M -$28.04M $28.82M
Free Cash Flow $194.8M $84.26M -$74.25M
YoY Change 65.89% -22.7% -184.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-26727
dei Entity Registrant Name
EntityRegistrantName
BioMarin Pharmaceutical Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
506-6700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
BMRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2274385000 usd
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
185473867 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
619802000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
587276000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
489945000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
426599000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
466507000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
373399000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
802315000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
776669000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
139029000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
110442000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
2517598000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
412503000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
507793000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1049464000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1035461000 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
369368000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388652000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
196199000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
196199000 usd
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1448912000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1449075000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
151797000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
151760000 usd
CY2022Q2 us-gaap Assets
Assets
6145841000 usd
CY2021Q4 us-gaap Assets
Assets
6003325000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
434773000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
491590000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
29954000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
48232000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
464727000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
539822000 usd
CY2022Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1081047000 usd
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1079077000 usd
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
15167000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
95260000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98519000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1641034000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1732585000 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
185452454 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
185452454 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
183912514 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
183912514 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
186000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
184000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5272666000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5191502000 usd
CY2022Q2 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9290000 usd
CY2021Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9689000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18472000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14432000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-777227000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-925689000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4504807000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4270740000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6145841000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6003325000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
533798000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
501693000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1053157000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
987723000 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
123126000 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
127062000 usd
us-gaap Cost Of Revenue
CostOfRevenue
240091000 usd
us-gaap Cost Of Revenue
CostOfRevenue
247228000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
158190000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
161107000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319026000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
309832000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
196835000 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
184161000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
391454000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
358479000 usd
CY2022Q2 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
16495000 usd
CY2021Q2 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17691000 usd
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
34107000 usd
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
35426000 usd
CY2022Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2021Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
108000000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
494646000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
490021000 usd
us-gaap Costs And Expenses
CostsAndExpenses
876678000 usd
us-gaap Costs And Expenses
CostsAndExpenses
950965000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
39152000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
11672000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
176479000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
36758000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2505000 usd
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4471000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4325000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
6910000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
3859000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
3817000 usd
us-gaap Interest Expense
InterestExpense
7665000 usd
us-gaap Interest Expense
InterestExpense
7621000 usd
CY2022Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2947000 usd
CY2021Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1830000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4101000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1337000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
34851000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14156000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
169038000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
37384000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7187000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1215000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20576000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7072000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27664000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
12941000 usd
us-gaap Net Income Loss
NetIncomeLoss
148462000 usd
us-gaap Net Income Loss
NetIncomeLoss
30312000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4504807000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185254000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182844000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
184710000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182311000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187448000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185427000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
191096000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185089000 shares
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
47013000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6998000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
152502000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
45512000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4391315000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
4162010000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4270740000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4106002000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4241571000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4504807000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4241571000 usd
us-gaap Net Income Loss
NetIncomeLoss
148462000 usd
us-gaap Net Income Loss
NetIncomeLoss
30312000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52614000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
55214000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2062000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2082000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3070000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1878000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
94911000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
104346000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
108000000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3455000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1204000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
12333000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1004000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1338000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4488000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
18000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
376000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
92562000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-17420000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1431000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6379000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
12001000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-34331000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-9149000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-321000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-76345000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-60884000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1576000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
585000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10795000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
196296000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55971000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48106000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
311598000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
348941000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
304805000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
484572000 usd
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
110000000 usd
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2739000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6400000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
908000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58083000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-191045000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
29493000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
27640000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
44377000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
38731000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
21054000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1122000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1941000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-381000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-37060000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13413000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
708000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
537000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32526000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7625000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
587276000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
649158000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
619802000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
641533000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
11821000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
10159000 usd
us-gaap Interest Paid Net
InterestPaidNet
5137000 usd
us-gaap Interest Paid Net
InterestPaidNet
5195000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
1012000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-9393000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
6563000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
1397000 usd
bmrn Number Of Commercial Products In Portfolio
NumberOfCommercialProductsInPortfolio
7 commercial_product
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1537944000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
150000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15844000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1522250000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
619802000 usd
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
104493000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
489945000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
412503000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1523467000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
719000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2518000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1521668000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
587276000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
426599000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
507793000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
80269000 usd
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
429486000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
415261000 usd
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
268336000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
281139000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
802315000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
776669000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1811263000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1756035000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
761799000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
720574000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1049464000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1035461000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
9500000 usd
us-gaap Depreciation
Depreciation
21200000 usd
CY2021Q2 us-gaap Depreciation
Depreciation
11800000 usd
us-gaap Depreciation
Depreciation
24300000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
689499000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
677350000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
320131000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
288698000 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
369368000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388652000 usd
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
199251000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
193003000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
127929000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
204446000 usd
CY2022Q2 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
62485000 usd
CY2021Q4 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
47987000 usd
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
15620000 usd
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
15215000 usd
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10224000 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6263000 usd
CY2022Q2 bmrn Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
10611000 usd
CY2021Q4 bmrn Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
10464000 usd
CY2022Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2472000 usd
CY2021Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1935000 usd
CY2022Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
1568000 usd
CY2021Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
1213000 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
305000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6956000 usd
CY2022Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
4308000 usd
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
4108000 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
434773000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
491590000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
108000000 usd
CY2022Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
42525000 usd
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
22775000 usd
CY2022Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
12072000 usd
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
7641000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
494646000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
490021000 usd
us-gaap Costs And Expenses
CostsAndExpenses
876678000 usd
us-gaap Costs And Expenses
CostsAndExpenses
950965000 usd
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
25500000 usd
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1100000000 usd
CY2022Q2 us-gaap Convertible Debt
ConvertibleDebt
1081047000 usd
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
1079077000 usd
CY2022Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1092837000 usd
CY2021Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1146204000 usd
CY2022Q2 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
22635000 usd
CY2022Q2 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
4127000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-841000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19349000 usd
CY2021Q2 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
-8450000 usd
CY2021Q2 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-2334000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-173000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5943000 usd
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
9136000 usd
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
8320000 usd
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-3224000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4040000 usd
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
9498000 usd
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-5086000 usd
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-616000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15200000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
533798000 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
501693000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1053157000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
987723000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47078000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54843000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
94911000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
104346000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
27664000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12941000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
148462000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
30312000 usd
CY2022Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
CY2021Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1871000 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
27664000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
12941000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
150333000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
30312000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185254000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182844000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
184710000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182311000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187448000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185427000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
191096000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185089000 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.80
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18994000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18504000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14803000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18310000 shares
bmrn Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
778000000 usd
CY2022Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
140800000 usd

Files In Submission

Name View Source Status
0001048477-22-000027-index-headers.html Edgar Link pending
0001048477-22-000027-index.html Edgar Link pending
0001048477-22-000027.txt Edgar Link pending
0001048477-22-000027-xbrl.zip Edgar Link pending
bmrn-20220630.htm Edgar Link pending
bmrn-20220630.xsd Edgar Link pending
bmrn-20220630_cal.xml Edgar Link unprocessable
bmrn-20220630_def.xml Edgar Link unprocessable
bmrn-20220630_htm.xml Edgar Link completed
bmrn-20220630_lab.xml Edgar Link unprocessable
bmrn-20220630_pre.xml Edgar Link unprocessable
exhibit311-30jun22x10q.htm Edgar Link pending
exhibit312-30jun22x10q.htm Edgar Link pending
exhibit321-30jun22x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending